First AD

Second AD

Treatment Goals and First-Line Therapy in PBC

Video content above is prompted by the following:

What are the treatment goals for patients with PBC?

How do treatment goals change based on the severity of the disease?

UDCA is recommended as the first-line pharmacological treatment for PBC. How does it work to treat the disease?

What are some challenges or limitations you encounter when using UDCA that may prompt a need to modify therapy?

How do you define biochemical response and when?

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Video Series

Expanding Treatment Options for Primary Biliary Cholangitis with Novel Therapies

Primary Biliary Cholangitis (PBC) treatment aims to alleviate symptoms, prevent disease progression, and improve quality of life. Treatment goals evolve with disease severity, focusing on symptom management in early stages and preventing complications in advanced stages. Ursodeoxycholic acid (UDCA) is the first-line treatment, working by improving bile flow and reducing liver inflammation. It is indicated for patients with early-stage PBC. Challenges with UDCA include incomplete biochemical response, necessitating therapy modification. Biochemical response is defined by specific liver function tests, typically assessed after six months of treatment.

The panel of experts outline the primary treatment goals for patients with primary biliary cholangitis (PBC), detailing how goals adjust based on disease severity, the role of ursodeoxycholic acid (UDCA) as first-line therapy, and the challenges that may require therapy modifications based on biochemical response.